Twist Bioscience에 대한 매도 수량은 투자자에게 Twist Bioscience의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Twist Bioscience (NASDAQ:TWST) 주식, 공매도 수량 보고

Twist Bioscience

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Mid Cap

News

Movers

ALHC

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 1. 쾨르 마이닝(NYSE:CDE)의 주식은 36.59% 상승했다. 이 회사는 네바다주에 확장된 로체스터(Rochester) 은-금 광산의 처리량 추세가 긍정적이라고 보고했다.

쾨르 마이닝, 뉴 골드 및 RH는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (9월 8일-9월 14일)

Equities

Markets

$BTC

ARKF

ARKW

AVAV

DKNG

GLBE

RDDT

RKLB

STNE

TWLO

TWOU

수요일에 캐시 우드의 아크 인베스트(Ark Invest)는 몇 가지 중요한 거래를 했다. 그 중 가장 눈에 띄는 것은 쇼피파이(NYSE:SHOP), 레딧(NYSE:RDDT)의 주식 매수, 그리고 코인베이스 글로벌(NASDAQ:COIN)의 주식 매각이다.

아크 인베스트는 쇼피파이 주식 $3,000만 이상 매입, 레딧도 매수, 코인베이스 주식은 매도

Twist Bioscience Corporation - Common Stock

Twist Bioscience Corp

Full year fiscal 2025 guidance:2
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Current</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$2,369</td>
<td colspan="1" rowspan="1">$2,391</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating margin3</td>
<td colspan="1" rowspan="1">23.0&nbsp;%</td>
<td colspan="1" rowspan="1">23.2&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS</td>
<td colspan="1" rowspan="1">$5.78</td>
<td colspan="1" rowspan="1">$5.87</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted revenue</td>
<td colspan="1" rowspan="1">$2,353</td>
<td colspan="1" rowspan="1">$2,375</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating margin</td>
<td colspan="1" rowspan="1">22.7&nbsp;%</td>
<td colspan="1" rowspan="1">22.8&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
<a href="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.html"><img src="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.jpg" alt="Key Call-Outs" /></a>

Guidance

JKHY

Jack Henry & Associates Sees FY25 EPS $5.78-$5.87 Vs $5.83 Est.; Revenue $2.353B-$2.375B Vs $2.37B Est.

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) narrows FY2024 sales outlook from $495.00 million-525.00 million to $500.00 million-510.00 million.

SWIM

Latham Group Narrows FY2024 Sales Guidance from $495.00M-525.00M to $500.00M-510.00M  VS Est. 512.39M

Meme cryptocurrency Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) has experienced a surge in trading volume and price activity leading up to the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a>
A Benzinga poll asks readers to choose whether a victory by Donald Trump or Kamala Harris in the election could have a more positive impact on Dogecoin in 2025.
What Happened: Dogecoin is up 12% to $0.1761 on Tuesday, with the meme cryptocurrency seeing increased activity likely related to the 2024 election <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s">and positive mentions </a>of the Department of Government Efficiency, or D.O.G.E. for short, by Elon Musk.
Musk is expected to join the Trump administration if the former president wins the 2024 election. In this role, Musk would seek to cut government inefficiencies and unnecessary departments, a role labeled under the D.O.G.E.
The Tesla CEO and billionaire mentioned D.O.G.E. during his<a href="https://www.benzinga.com/general/education/24/11/41752565/if-you-invested-1-000-in-tesla-stock-the-first-time-elon-musk-was-on-the-joe-rogan-podcast-here"> most recent appearance</a> Monday on "The Joe Rogan Experience" podcast, which is likely contributing to Dogecoin's strong movement on Tuesday.
"For Dogecoin's future in 2025, who would be the better president: Kamala Harris or Donald Trump?" Benzinga recently asked.
The results were:
<ul>
<li>Donald Trump: 72%</li>
<li>Kamala Harris: 28%</li>
</ul>
The Benzinga poll found that respondents believe Trump would be more favorable for the future of Dogecoin, which may not come as a surprise given the former president&#8217;s reputation as a more pro-crypto leader.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Trump, who previously <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38749745/if-you-invested-1-000-in-bitcoin-when-donald-trump-said-the-cryptos-value-was-based-on-thi">spoke out against Bitcoin, </a>reversed course and has appealed to cryptocurrency investors ahead of the 2024 election.
If Trump wins the 2024 election, cryptocurrency investors expect the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies to rise with a more crypto-friendly government in place and the likelihood that SEC Chair Gary Gensler will be replaced.
While Harris has not been as vocal on cryptocurrency as Trump, there is belief that she <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41322645/mark-cuban-defends-kamala-harris-crypto-knowledge-appears-to-take-dig-at-trump-for-selling">could look to advance</a> the sector forward if she wins the election.
Either way, Dogecoin could see high volatility during the week as the 2024 election outcome is expected to take some time to make official.
With a price of $0.1761 on Tuesday, Dogecoin is nearing its one-month high of $0.1792.
Over the last 52 weeks, Dogecoin has traded between $0.07028 and $0.2266. Dogecoin hit all-time highs of $0.7376 back in May 2021.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41410605/if-you-invested-100-in-dogecoin-when-elon-musk-first-tweeted-about-the-meme-crypto-heres-h">If You Invested $100 In Dogecoin When Elon Musk First Tweeted About The Meme Crypto, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
The study was conducted by Benzinga from Nov. 4 through Nov. 5, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 134 adults.
Image created with Shutterstock and Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$DOGE

Dogecoin Jumps On Election Day: Poll Asks If Trump Or Harris Victory Will Spark 2025 Rally

WIIM

Devon Energy shares are trading higher following a Q3 earnings beat.

Ashford Hospitality Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) reported quarterly AFFO of $(1.71) per share which missed the analyst consensus estimate of $(0.97) by 76.29 percent. This is a 311.11 percent decrease over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $276.60 million which beat the analyst consensus estimate of $268.97 million by 2.84 percent. This is a 19.36 percent decrease over sales of $343.01 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Ashford Hospitality Trust Q3 2024 AFFO $(1.71) Misses $(0.97) Estimate, Sales $276.60M Beat $268.97M Estimate

Jack Henry &amp; Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.61 by 1.24 percent. This is a 17.27 percent increase over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $600.98 million which beat the analyst consensus estimate of $600.11 million by 0.15 percent. This is a 5.18 percent increase over sales of $571.37 million the same period last year.

Jack Henry & Associates Q1 EPS $1.63 Beats $1.61 Estimate, Sales $600.98M Beat $600.11M Estimate

B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.20 by 35 percent. The company reported quarterly sales of $461.10 million which missed the analyst consensus estimate of $473.12 million by 2.54 percent. This is a 8.28 percent decrease over sales of $502.73 million the same period last year.

B&G Foods Q3 2024 Adj EPS $0.13 Misses $0.20 Estimate, Sales $461.10M Miss $473.12M Estimate

NHI is updating its 2024 annual guidance range which includes the following:
NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54;
Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and
Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million;
NAREIT FFO and Normalized FFO revised guidance is primarily due to lower cash lease revenue and interest income assumptions, and a $3.6 million non-cash increase to the credit loss reserve attributable to Senior Living Management. This was partially offset by acquisitions closed since August 2024 funded primarily with forward equity proceeds;
Normalized FAD revised guidance is primarily due to acquisitions closed since August 2024 offset by lower cash lease revenue and interest income assumptions attributable to Senior Living Management.

National Health Investors Updates FY24 NAREIT FFO Per Diluted Share From $4.50-$4.54 To $4.39-$4.41; Normalized FFO Per Diluted Share From $4.52-$4.56 To $4.43-$4.44

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.03) by 2800 percent. This is a 245 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $88.43 million which missed the analyst consensus estimate of $94.21 million by 6.14 percent. This is a 1.75 percent increase over sales of $86.91 million the same period last year.

AVNW

Aviat Networks Q1 Adj $(0.87) Misses $(0.03) Estimate, Sales $88.43M Miss $94.21M Estimate

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) lowers FY2024 sales outlook from $231.00 million-235.00 million to $230.00 million-232.00 million.

VTEX

Vtex Lowers FY2024 Sales Guidance from $231.00M-235.00M to $230.00M-232.00M.

MASI

Masimo Sees Q4 Revenue $581M-$611M; Q4 Adj. EPS $1.35-$1.50

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) sees Q4 sales of $64.800 million-66.800 million vs $67.57 million estimate.

Vtex Sees Q4 Sales $64.800M-66.800M vs $67.57M Est.

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.02) by 3.92 percent. The company reported quarterly sales of $12.500 million which beat the analyst consensus estimate of $11.199 million by 11.62 percent.

SNDX

Syndax Pharmaceuticals Q3 2024 GAAP EPS $(0.98) Beats $(1.02) Estimate, Sales $12.500M Beat $11.199M Estimate

Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. The company reported quarterly sales of $45.086 million which beat the analyst consensus estimate of $43.484 million by 3.68 percent. This is a 10.62 percent increase over sales of $40.758 million the same period last year.

TMCI

Treace Medical Concepts Q3 2024 GAAP EPS $(0.25) Beats $(0.27) Estimate, Sales $45.086M Beat $43.484M Estimate

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.14 by 14.04 percent.

Devon Energy Q3 2024 GAAP EPS $1.30 Beats $1.14 Estimate

Coupang (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.01 by 500 percent. The company reported quarterly sales of $7.90 billion which beat the analyst consensus estimate of $7.76 billion by 1.79 percent. This is a 27.75 percent increase over sales of $6.18 billion the same period last year.

CPNG

Coupang Q3 2024 Adj EPS $0.06 Beats $0.01 Estimate, Sales $7.90B Beat $7.76B Estimate

Ever wondered <a href="https://www.benzinga.com/personal-finance/24/10/41193824/are-you-rich-enough-to-be-in-the-top-1-heres-both-the-income-and-net-worth-you-need-to-rank-amon">how your finances measure up?</a> You're not alone. We often think about where we stand compared to others financially – though few of us like to admit it. Getting a sense of your financial health can be motivating, especially when it's not about competition but about setting realistic goals for yourself.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved? <a href="https://www.benzinga.com/money/red-ventures" target="_blank" rel="noreferrer noopener">The percentage may shock you</a>.</li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>
What is Net Worth, Really?
Before diving into numbers, clarifying what "net worth" means is important. Simply put, it's what you own (assets) minus what you owe (liabilities). Assets include things like your home, car, investments and savings. Liabilities are things like mortgages, credit card debt and student loans. Think of net worth as a quick snapshot of your financial health. It's a bigger picture than income alone, revealing how much you've kept.
See Also: Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a>
Net Worth by Income Level
According to the Federal Reserve's latest data, here's how net worth varies across different income brackets:
<ul>
<li>Under $34,600: Median net worth of $14,000, average of $129,700</li>
<li>$34,600-$59,499: Median of $71,000, average of $218,700</li>
<li>$59,500-$91,899: Median of $159,300, average of $385,400</li>
<li>$91,900-$153,099: Median of $307,200, average of $636,800</li>
<li>$153,100-$245,399: Median of $747,000, average of $1,264,700</li>
<li>$245,400 and higher: Median of $2,556,200, average of $6,629,600</li>
</ul>
Upper-income households in the U.S. generally have a net worth significantly higher than lower-income households. According to Pew Research Center, the median net worth of upper-income households is roughly 7.3 times greater than that of middle-income households, and 75 times that of lower-income households.
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
What You Can Learn from the Data
There are a few standout takeaways:
Median vs. Average: The U.S. household median net worth is $192,700, while the average is around $1.06 million. The gap highlights how high-net-worth individuals skew the overall average.
Age Matters: Net worth tends to peak for those aged 65-74, averaging around $1.78 million. Years of saving and investing build up.
Education's Impact: A college degree matters here – graduates have over 11 times the net worth of people without a high school diploma.
Location, Location, Location: Urban dwellers typically have higher net worthy than those in rural areas, largely due to property values.
Wealth Gap: Unfortunately, the racial wealth gap remains stark, with white households holding considerably higher net worthy on average than Black and Latino households.
Trending: According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually, <a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor" target="_blank" rel="noreferrer noopener">here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a>
Steps to Boost Your Net Worth
Regardless of where you currently fall, there are practical ways to improve your financial standing:
<ul>
<li>Pay Off High-Interest Debt: Start with credit card balances and other high-interest debts, which can drain your finances fast.</li>
</ul>
<ul>
<li>Save and Invest: Aim to set aside at least 20% of your income and automate it if you can. Investing early helps, too.</li>
</ul>
<ul>
<li>Leverage Retirement Accounts: Contribute to 401(k)s or IRAs, especially if your employer matches contributions.</li>
</ul>
<ul>
<li>Diversify: Spread your investments across stocks, bonds and real estate to manage risk and grow wealth.</li>
</ul>
<ul>
<li>Find Extra Income Streams: Side hustles, freelance work or passive income can boost your finances.</li>
</ul>
See Also: <a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a>
<ul>
<li>Keep Learning: Educate yourself about personal finance and stay updated on tax strategies and investment options.</li>
</ul>
<ul>
<li>Live Below Your Means: Resist lifestyle inflation even as your income grows. Focus on assets, not material things.</li>
</ul>
<ul>
<li>Invest in Yourself: Whether it's more education or a new skill, growing your potential can lead to better income.</li>
</ul>
<ul>
<li>Check In on Your Goals: Adjust your financial plan as your life and income evolve.</li>
</ul>
<ul>
<li>Seek Professional Guidance: A <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">financial advisor can help you</a> strategize if it feels overwhelming.</li>
</ul>
Comparing your finances to others can motivate you, but remember that everyone's journey is different. Focus on realistic, personal goals that fit your life. Building wealth takes time – it's a marathon, not a sprint. With steady, smart choices, you'll see growth in your net worth over time. Regardless of where you stand now, there's always room to move toward a more secure financial future.
This story was updated to reflect updated research numbers for upper household income net worth vs. lower-income households.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211; <a href="https://www.benzinga.com/money/retire-5mil-nest-egg" target="_blank" rel="noreferrer noopener">How does it compare to the average?</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Personal Finance

Are You Richer Or Poorer Than Your Peers? Here's A Look At The Average Net Worth For Your Income

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) narrows FY2024 sales outlook from $56.00 million-58.00 million to $56.90 million-57.90 million.

Arteris Narrows FY2024 Sales Guidance from $56.00M-58.00M to $56.90M-57.90M

Masimo Lowers FY24 Revenue From $2.085B-$2.135B To $2.075B-$2.105B Vs $2.100B Est; Raises FY24 Adj. EPS From $3.80-$4.00 To $3.95-$4.10 Vs $3.88 Est

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) sees Q4 sales of $14.700 million-15.700 million vs $14.92 million estimate.

Arteris Sees Q4 Sales $14.700M-15.700M vs $14.92M Est

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.&nbsp;



Investors raced to sell off their stock and repay their loans, causing markets to crash.&nbsp; A weaker market allows investors to purchase stock at discounted prices. Indeed, the Healthcare sector is positioned to grow to $819 billion by 2027 at a robust 7% CAGR. One of the strongest growing sectors within the industry is health tech from generative AI use cases in the space.



Investors should take advantage of current market conditions and buy these Healthcare <a href="https://investorplace.com/industries/technology/artificial-intelligence/">AI stocks</a>.



<h2>Twist Bioscience (TWST)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/11/twst1600-300x169.png" alt="Scientific handling a light microscope examines a laboratory sample for pharmaceutical bioscience research. Concept of science, laboratory and study of diseases. Twist Biosciences (TWST)"><div>Source: dhvstockphoto / Shutterstock.com</div></div>Twist BioScience (NASDAQ:<a href="https://investorplace.com/stock-quotes/twst-stock-quote/">TWST</a>) is a biotechnology company that manufactures synthetic DNA products. <a href="https://finance.yahoo.com/quote/VST/analysis/">Yahoo! Finance</a> reports seven analysts predicting a 1-year price range on TWST between $31.11 and $65.00, with an average price target of $51.91.&nbsp;



TWST reported financials that are characteristic of a biotechnology company. Q2 2024 revenue was strong, growing 27.81% YOY. However, the company has yet to return a profit this quarter, which has continued for the past year. There has been a trend of decreasing assets for the company, with total assets decreasing by 21.25% for Q2 2024. This marks the biggest decrease in the past year. However, the company&rsquo;s improving liquidity offers hope to investors. A 464.11% increase in free cash flow for Q2 2024 demonstrates management handling operational expenses.&nbsp;



The company may have a reversal in the future from a partnership with bitBiome. Both companies partnered to create an enzyme screening kit with pharmaceutical applications. The enzyme (transaminase) within the kit is specialized in synthesizing active pharmaceutical ingredients while serving as an environmentally safe alternative to other methods. TWST recently <a href="https://www.businesswire.com/news/home/20240604321380/en/Twist-Bioscience-Announces-Participation-in-Department-of-Commerce-Consortium-Dedicated-to-AI-Safety">joined</a> the U.S. AI Safety Institute Consortium (ASIC) to promote ethical AI development. Being environmentally and ethically conscious with upside potential makes TWST one of the healthcare AI stocks to buy.



<h2>GE Healthcare (GEHC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/01/gehc1600-300x169.png" alt="GE Healthcare (GEHC) sign. GE Healthcare is an American company founded in 2014 and spun off from GE in 2023."><div>Source: testing / Shutterstock.com</div></div>GE Healthcare (NASDAQ:<a href="https://investorplace.com/stock-quotes/gehc-stock-quote/">GEHC</a>) is a healthcare company that provides digital infrastructure, data analytics and decision support tools for various healthcare applications. <a href="https://finance.yahoo.com/quote/GEHC/analysis/">Yahoo! Finance</a> reports 17 analysts predicting a 1-year price range on GEHC between $84.00 and $105.00, with an average price target of $93.95.&nbsp;



GEHC has solid financials for Q2 2024. The company barely missed on revenue but beat EPS expectations for the quarter. Revenue grew <a href="https://www.google.com/finance/quote/GEHC:NASDAQ">0.46%</a> year over year, and net profit margin grew 1.84% year over year. Additionally, management has improved its handling of operational expenditures, with free cash flow growing 131.81% year over year.&nbsp;



GEHC could be primed for a breakout with an <a href="https://aws.amazon.com/blogs/industries/aws-and-ge-healthcare-are-teaming-up-to-use-ai-to-improve-patient-care/">AWS partnership</a>. GEHC has partnered with Amazon (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/">AMZN</a>) to develop AI models for healthcare applications. Specifically, the partnership aims to aggregate data from doctor notes, x-rays and other medical tests to develop healthcare insights. For instance, compositing data in such a manner streamlines future similar processes by establishing precedents of solutions and treatments. The potential this AWS partnership carries, alongside strong financials, makes GEHC one of the Healthcare AI stocks to watch.



<h2>Clover Health (CLOV)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/clov_clover_health_1600-300x169.png" alt="Clover Health (CLOV) company logo on a website with blurry stock market developments in the background, seen on a computer screen through a magnifying glass."><div>Source: Dennis Diatel / Shutterstock.com</div></div>Clover Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/clov-stock-quote/">CLOV</a>) is a healthcare company that provides Medicare Advantage insurance plans and operates as a direct contracting entity of the US government. <a href="https://finance.yahoo.com/quote/CLOV/analysis/">Yahoo Finance!</a> reports three analysts covering the stock with one buy rating and two hold ratings for July 2024.



CLOV reported very strong financials for Q2 2024. While revenue grew by <a href="https://www.google.com/finance/quote/CLOV:NASDAQ">7%</a>, the net profit margin grew by 75.33%. Moreover, this quarter marks the first quarter of positive net income for the company. As a result of such good earnings, management has improved full-year guidance. The level of improvement is best seen through EBITDA projections. Originally, EBITDA guidance was between a $20 million loss and gain; now, it is between $50 and $65 million.



The company has developed Clover Assistant, an AI assistant SaaS. The assistant is meant to serve as a clinical decision-making tool for payers and providers based on the patient&rsquo;s medical and financial data. Furthermore, the assistant tool allows CLOV to expand in areas that Medicare Advantage doesn&rsquo;t reach. It also has the potential for one-on-one use with Medicare Advantage patients as a recurring revenue stream on a use-by-use basis. Developments with AI and an improving financial outlook make CLOV one of the <a href="https://investorplace.com/industries/healthcare/">healthcare stocks</a> for investors to consider.



On the date of publication, Matthew Rodrigues&nbsp;did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Matthew Rodrigues is a college student studying Business at UC Berkeley Haas. He believes detailed research and correct interpretation of current events is what leads to investment success.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/08/3-healthcare-ai-stocks-positioned-for-potential-breakthroughs/">3 Healthcare AI Stocks Positioned for Potential Breakthroughs</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Healthcare AI Stocks Positioned for Potential Breakthroughs

Invesco Main Street Small Cap Fund Q2 2024 Review

Invesco Small Cap Growth Fund Q2 2024 Review

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CureVac (CVAC – Research Report), Vericel (VCEL – Research Report...

Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)

Interest Rate Regimes And ARKG: Underperformance Explained

Barclays analyst Luke Sergott maintained a Buy rating on Twist Bioscience (TWST – Research Report) today and set a price target of $55.00. The comp...

Barclays Sticks to Their Buy Rating for Twist Bioscience (TWST)

Analyst Catherine Ramsey Schulte of Robert W. Baird maintained a Buy rating on Twist Bioscience (TWST – Research Report), retaining the price targe...

Positive Outlook and Strong Pricing Strategy Justify Buy Rating for Twist Bioscience

XOMA Royalty Corporation (XOMA) has entered into a $15 million royalty monetization arrangement with Twist Bioscience Corporation (TWST) to acquire...

Xoma enters $15M royalty monetization arrangement with Twist Bioscience

Twist Bioscience enters into purchase agreement with XOMA Royalty

Leerink Partners analyst Puneet Souda maintained a Hold rating on Twist Bioscience (TWST – Research Report) on October 22. The company's shares ope...

Leerink Partners Remains a Hold on Twist Bioscience (TWST)

ACHC

ADMA

ATKR

BLFS

CLOV

CRDO

CVAC

CYRX

CYTK

DAVA

EXAS

FRSH

FTAI

FTAIM

FTAIN

FTAIO

FTAIP

GEHC

GKOS

GLOB

GTES

GTLB

GWRE

INSP

ITGR

ITRI

KNSL

LSCC

MANH

MTSI

NTLA

ONON

ONTO

PACB

PFSI

PYCR

PZZA

RARE

RGEN

RMBS

SDGR

SITE

SITM

SKWD

SMCI

TMDX

TMXXF

VCEL

WING

XOMA

Press Releases

Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Twist Bioscience to Present at Baird Global Healthcare Conference 2024

Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels

Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance

Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024

Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Comments

Twist Bioscience

매도 수량

Twist Bioscience (NASDAQ:TWST) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌